We are here to help   +49 (0) 2241.255 15 0
  • 0Shopping Cart
  • Product Types
      • Coagulation Proteins
      • Enzymes
      • Cells and Media
      • Cytokines and Chemokines
      • COVID-19 / SARS-CoV-2
      • Molecular Biology
      • Stem Cells / iPSC
      • Adhesion Molecules
      • Tissue Dissociation
      • Matrix Proteins / Bioprinting
      • Gene Editing / CRISPR / TARGATT
  • Brands
  • Company
  • Services
  • Career
  • News
  • Contact
  • Menu Menu
Home |Products|Cells and Media|Human Vitronectin, Solution

Human Vitronectin, Solution

Cat.-Nr.: 5051-0.1MG

Description

Vitronectin is a monomeric glycoprotein used to promote cell attachment, migration, proliferation and differentiation in a broad number of cell lines and types. This product has been purified from human plasma where it is found as a mixture of 75kDa and 65kDa polypeptides.

Vitronectin’s primary use in cell culture is related to cell adhesion. It also binds to heparin and collagen.

Vitronectin is ideal for coating of surfaces. The optimal concentration for cell attachment and culture may differ for various cell types. Vitronectin has been used at a final coating concentration as low as 50 ng/cm2 on plasticware. It is provided in user-friendly packaging for use and storage. Vitronectin is sterile filtered and is supplied as a ready to use solution after thawing and concentration adjustment. This product is shipped separately on dry ice.

  • SUPPLIER:

    Advanced BioMatrix

  • STATUS:

    In Stock

  • SIZE:

    0,1 mg

  • Overview
  • Related Files
  • References

Overview

  • Species: Human
  • Additional Attributes: Extracellular Matrix
  • Features:0,5 mg/ml

Related Files

Datasheet
Certificate of Origin

References

  • Wiley, Luke A., et al. "Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration." Human gene therapy 27.10 (2016): 835-846.
  • Wiley, Luke A., et al. "Generation of xeno‐free, cGMP‐compliant patient‐specific iPSCs from skin biopsy." Current protocols in stem cell biology 42.1 (2017): 4A-12.
  • Dwyer, Sheila Figel, Lingqiu Gao, and Irwin H. Gelman. "Identification of novel focal adhesion kinase substrates: Role for FAK in NFκB signaling." International journal of biological sciences 11.4 (2015): 404.
  • Wiley, Luke A., et al. "cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness." Scientific reports 6 (2016): 30742.
  • Kittur, Harsha, et al. "Probing Cell Adhesion Profiles with a Microscale Adhesive Choice Assay." Biophysical journal 113.8 (2017): 1858-1867.
  • Dwyer, Sheila Figel, and Irwin H. Gelman. "Cross-phosphorylation and interaction between Src/FAK and MAPKAP5/PRAK in early focal adhesions controls cell motility." Journal of cancer biology & research 2.1 (2014).
  • Worthington, Kristan S., et al. "Two-photon polymerization for production of human iPSC-derived retinal cell grafts." Acta biomaterialia 55 (2017): 385-395.

RELATED PRODUCTS


  • TeloCol™-3, purified Bovine Collagen, Solution

  • VitroCol®, Human Collagen, Solution

  • RatCol® Rat Tail Type I Collagen + Neut. Solution

  • PureCol®, Bovine Collagen

  • Imprint
  • Privacy policy
Human Type I Collagen Coated Beads, Sterile ICAM2, Human Recombinant
Scroll to top